Core Viewpoint - The company has made significant progress in its licensing agreements for the innovative anti-PD-1 monoclonal antibody, Surufatinib, with KGBio and Abbott, aiming to enhance its international market presence and product accessibility [1][13]. Group 1: Previous Cooperation - The company’s subsidiary, Fuhong Hanlin, signed exclusive licensing agreements with KGBio in September 2019 and August 2023 for the commercialization of Surufatinib in Southeast Asia, the Middle East, and North Africa [1]. - On December 31, 2024, Fuhong Hanlin entered into a licensing agreement with Abbott for the commercialization of Surufatinib in Latin America and the Caribbean [1]. Group 2: Recent Developments - On February 24, 2026, Fuhong Hanlin and KGBio signed a revision and partial termination agreement, terminating the 2023 exclusive licensing agreement and the exclusive commercialization rights in all regions except Indonesia [1][9]. - Fuhong Hanlin and Abbott signed a revision to the 2024 licensing agreement, expanding the licensing area and adding regulatory and sales milestone payments [2][10]. Group 3: Product Information - Surufatinib is an innovative anti-PD-1 monoclonal antibody developed by the company, approved for marketing in several countries, including China, the EU, and various Southeast Asian nations [4]. - The drug has received orphan drug designation in multiple regions and is undergoing clinical trials for various cancers, including lung and gastric cancers [4]. Group 4: Financial Aspects - The global sales of PD-1 targeted monoclonal antibodies are projected to be approximately $45.7 billion in 2024 [5]. - Under the revised agreement with Abbott, additional milestone payments of up to $46 million for regulatory achievements and up to $80 million for sales achievements are stipulated [11]. Group 5: Impact on the Company - The termination of certain commercialization rights with KGBio and the expansion of collaboration with Abbott are aimed at advancing the overseas market expansion of the company’s PD-1 monoclonal antibody product, enhancing its international recognition and accessibility [13].